Bora Biologics Expands CDMO Operations in San Diego Following Tanvex Acquisition

Bora Biologics, a subsidiary of Tanvex Biopharma, has announced a significant expansion of its contract development and manufacturing organization (CDMO) operations at its San Diego facility. This move comes in the wake of Tanvex's acquisition of Bora's CDMO business earlier this year, marking a new chapter in the company's growth strategy.

Expansion Details and Capabilities

The expansion project will add 8,075 square feet of production space to the existing San Diego site. Key additions include:

• Two 2,000-liter bioreactors
• Design plans accommodating future bioreactor expansion up to 5,000 liters

John Mosack, General Manager and VP of Operations at Bora's San Diego facility, emphasized the impact of this expansion: "We will be able to offer our customers 2000L commercial capacity with the ability to purify modern high-titer cell culture processes."

Strategic Acquisitions and Market Positioning

The San Diego expansion is part of a larger series of strategic moves by Bora Pharmaceuticals and its affiliates:

• January 2025: Tanvex completed the acquisition of Bora's CDMO business, rebranding it as Bora Biologics
• August 2024: Bora Pharma acquired a 30.5% stake in Tanvex, a fellow Taiwanese drugmaker
• June 2024: Bora invested $30 million to acquire Emergent BioSolutions' fill-finish drug product facility in Baltimore
• January 2024: $210 million acquisition of Upsher-Smith Laboratories, establishing Bora's first U.S. presence
• 2022: Acquisition of TWi Pharmaceuticals and Eden Biologics' CDMO business

These acquisitions have significantly expanded Bora's manufacturing capabilities and global footprint, particularly in the United States.

Industry Implications

The expansion of Bora Biologics' San Diego facility underscores the growing demand for advanced biopharmaceutical manufacturing capabilities. As the industry continues to evolve, companies are investing heavily in expanding their CDMO operations to meet the needs of modern drug development and production processes.

The addition of large-scale bioreactors and the potential for future expansion indicate Bora's commitment to serving clients with high-volume, high-titer biologics production needs. This move positions the company to compete more effectively in the rapidly growing biologics market, where manufacturing capacity and expertise are critical differentiators.